A full-service biomarker assay development and commercialization company that uniquely combines expertise in clinical biomarker diagnostics with access to intellectual property, a broad range of technology platforms, and full-service central laboratory for clinical trials that is licensed under CLIA/CAP and compliant with GLP/GCP regulations. Pathway Diagnostics was acquired by Quest Laboratories (NYSE:DGX).
Pathway Dx
